Client
- Top 20 pharma company, Global, UK and France market access teams
Challenge
- Phase 2/3 protocol finalisation timings meant that NICE and HAS advice was required by the R&D team within months
- Delivering the first phase of the project – a briefing book to NICE by early April 2020 – during the initial months of COVID
Approach
- redthread worked closely as a key part of the 4-person core project team to research, write and ultimately deliver a comprehensive briefing book to NICE from a kick off in late December to submission in early April
- A clear outline, and detailed and accurate first draft enabled the team to focus internal conversations on stakeholder management and clearly defining questions and company positions
- redthread supported all internal stakeholder conversations, and in many cases were trusted to liaise directly with key global R&D colleagues on behalf of the project team
Result
- Exceptionally high-quality dossier submitted to NICE for which only two clarification questions were received
- Our client commissioned us for a follow-up project supporting early dialogue with HAS for the same asset in a different indication
“I think it’s fair to say that the number of questions asked really reflects the quality of the briefing book we submitted – really well done guys”
UK Market Access Manager, Top 20 pharma
“You guys are the best!!!”
Global Value & Access Lead, Top 20 pharma
